MetaVia Inc. (MTVA) Stock Jumps After Reverse Split: What the New Price, Trial Data and 2026 Forecast Mean for Investors
MetaVia Inc. (NASDAQ: MTVA) has just pulled off a dramatic reset. After a 1‑for‑11 reverse stock split and a burst of upbeat clinical news, the tiny cardiometabolic biotech has seen its share price jump into the single digits again — but the business is still early‑stage, loss‑making, and highly speculative. As of December 6, 2025, MetaVia stock trades around $8.18 per share, up almost 12% in the last 24 hours, with a market capitalization of roughly $17 million.TradingView+1 Below is a deep dive into the latest MTVA stock news, reverse split mechanics, clinical pipeline, financials, analyst forecasts and key risks
